BR112018003123A2 - composição, enema, cepa isolada, método para tratamento e/ou prevenção de uma condição gastrointestinal, e, uso de uma composição, de um enema ou de uma ou mais de uma cepa bacteriana isolada - Google Patents
composição, enema, cepa isolada, método para tratamento e/ou prevenção de uma condição gastrointestinal, e, uso de uma composição, de um enema ou de uma ou mais de uma cepa bacteriana isoladaInfo
- Publication number
- BR112018003123A2 BR112018003123A2 BR112018003123A BR112018003123A BR112018003123A2 BR 112018003123 A2 BR112018003123 A2 BR 112018003123A2 BR 112018003123 A BR112018003123 A BR 112018003123A BR 112018003123 A BR112018003123 A BR 112018003123A BR 112018003123 A2 BR112018003123 A2 BR 112018003123A2
- Authority
- BR
- Brazil
- Prior art keywords
- isolated
- enema
- strain
- composition
- plantarum
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/24—Lactobacillus brevis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/25—Lactobacillus plantarum
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
a presente invenção refere-se a uma composição para uso no tratamento e/ou na prevenção de uma condição gastrointestinal, compreendendo pelo menos uma cepa de lactobacillus, em que a cepa de lactobacillus é escolhida do grupo consistindo em uma cepa de l. salivarius, três cepas de l. plantarum e uma cepa de l. brevis, em que a cepa de l. salivarius é l. salivarius cw30 (lmg p-28887), em que as cepas de l. plantarum são l. plantarum y1an734 (lmg p-28886), l. plantarum sh1313 (lmg p-28884), e l. plantarum ks11 (lmg p-28885), e em que a cepa de l. brevis é l. brevis sh111 (lmg p-28888). a presente invenção refere-se, também, a um enema compreendendo uma composição de acordo com a presente invenção. a presente invenção refere-se, outrossim, a uma cepa isolada escolhida do grupo dentre l. salivarius cw30 (lmg p-28887), l. plantarum y1an734 (lmg p-28886), l. plantarum sh1313 (lmg p-28884), l. plantarum ks11 (lmg p-28885) e l. brevis sh111 (lmg p-28888). a presente invenção refere-se, também, a uma cepa isolada de l. salivarius cw30 (lmg p-28887) para uso no tratamento e/ou na prevenção de uma infecção causada por clostridium difficile nap/027.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1551099-3 | 2015-08-25 | ||
| SE1551099 | 2015-08-25 | ||
| PCT/SE2016/050787 WO2017034460A1 (en) | 2015-08-25 | 2016-08-23 | Composition and method for treatment and prophylaxis of intestinal infection and inflammation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112018003123A2 true BR112018003123A2 (pt) | 2018-09-25 |
| BR112018003123B1 BR112018003123B1 (pt) | 2021-09-28 |
Family
ID=58100550
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018003123-2A BR112018003123B1 (pt) | 2015-08-25 | 2016-08-23 | Composição, enema, e, uso de uma composição, de um enema ou de uma ou mais de uma cepa bacteriana isolada |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10632159B2 (pt) |
| EP (1) | EP3341001B1 (pt) |
| JP (1) | JP6957452B2 (pt) |
| KR (1) | KR102656709B1 (pt) |
| CN (1) | CN108135948B (pt) |
| AU (2) | AU2016312870B2 (pt) |
| BR (1) | BR112018003123B1 (pt) |
| CA (1) | CA2995071A1 (pt) |
| DK (1) | DK3341001T3 (pt) |
| ES (1) | ES2909430T3 (pt) |
| IL (1) | IL257568A (pt) |
| MX (1) | MX2018002093A (pt) |
| PL (1) | PL3341001T3 (pt) |
| RU (1) | RU2738803C2 (pt) |
| WO (1) | WO2017034460A1 (pt) |
| ZA (1) | ZA201801266B (pt) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7015674B2 (ja) * | 2017-10-27 | 2022-02-15 | 日清食品ホールディングス株式会社 | 制御性ｔ細胞の分化誘導剤及び分化誘導方法 |
| JP2019187251A (ja) * | 2018-04-19 | 2019-10-31 | 国立研究開発法人農業・食品産業技術総合研究機構 | 発酵物の製造方法及び発酵物 |
| WO2020180037A1 (ko) * | 2019-03-04 | 2020-09-10 | 경북대학교 산학협력단 | 인간 장내 미생물 군집 모사 배양용 조성물, 혐기 배양 체계를 이용한 인간 장내 미생물 군집의 모사 배양 방법, 이에 의해 제조된 미생물 제제 및 이의 용도 |
| CN110129221B (zh) * | 2019-05-06 | 2022-05-17 | 福建晋江国食文化传媒有限公司 | 乳酸菌hwn19菌株及其应用 |
| CN111358798A (zh) * | 2020-03-13 | 2020-07-03 | 暨南大学 | 低聚糖阿魏酸酯的新应用 |
| WO2022039561A1 (ko) * | 2020-08-21 | 2022-02-24 | 서울대학교산학협력단 | 클로스트리디움 디피실리 감염의 치료 또는 예방용 조성물 |
| KR102488609B1 (ko) * | 2020-09-24 | 2023-01-12 | 국립낙동강생물자원관 | 장내 유해세균 억제 기능을 가진 락토바실러스 파라부크네리 nsmj16 (kacc81129bp) 및 락토바실러스 브레비스 nsmj23(kacc81130bp) |
| KR102363975B1 (ko) * | 2020-12-11 | 2022-02-17 | 주식회사 바이오뱅크힐링 | 락토바실러스 플란타룸 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
| CN112625983B (zh) * | 2021-03-05 | 2021-05-28 | 山东中科嘉亿生物工程有限公司 | 一种对腹泻有治疗效果的干酪乳杆菌L.Casei21及其应用 |
| US20230398159A1 (en) * | 2021-09-22 | 2023-12-14 | Asahi Biocycle Co., Ltd. | Composition for prophylaxis of enteritis in avian comprising lactobacillus plantarum strain |
| CN115466699B (zh) * | 2022-09-28 | 2023-03-31 | 成都大熊猫繁育研究基地 | 熊猫源唾液乳杆菌及在治疗或预防炎症性肠病中的应用 |
| CN116875520A (zh) * | 2023-07-12 | 2023-10-13 | 吉林农业大学 | 表达核糖体失活蛋白的乳酸菌及其在抗轮状病毒中的应用 |
| KR102628942B1 (ko) * | 2023-08-08 | 2024-01-26 | 주식회사 바이오뱅크힐링 | 레비락토바실러스 브레비스 균주, 및 그의 유래의 소포체및 그의 항염증 및 항균 용도 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1306716B1 (it) * | 1999-06-21 | 2001-10-02 | Mendes S U R L | Associazione di batteri lattici e suo uso per la prevenzione e/o iltrattamento terapeutico di infezioni e di stati infiammatori. |
| PE20030274A1 (es) * | 2001-07-26 | 2003-05-08 | Alimentary Health Ltd | Cepas de lactobacillus salivarius |
| ES2561629T3 (es) * | 2005-09-28 | 2016-02-29 | Nordisk Rebalance A/S | Tratamiento del SII usando como efectores de tratamiento tanto bacterias probióticas como cereales fermentados |
| WO2008064521A1 (fr) * | 2006-11-30 | 2008-06-05 | Pharmapep Research & Development (Shenzhen) Co., Ltd. | Lactobacillus fermentum cms-h002 et son utilisation |
| CA2704009C (en) * | 2007-10-11 | 2016-08-16 | Fayrefield Foods Limited | Preparation, use of preparation for treatment, and method of treatment of intestinal infection |
| WO2012142605A1 (en) * | 2011-04-15 | 2012-10-18 | Samaritan Health Services | Rapid recolonization deployment agent |
| US9579353B2 (en) * | 2011-06-10 | 2017-02-28 | Prothera, Inc. | Pharmaceutical compositions containing pediococcus and methods for reducing the symptoms of gastroenterological syndromes |
| JP2014166972A (ja) * | 2013-02-28 | 2014-09-11 | Kagome Co Ltd | 腸炎抑制剤及び飲食品 |
| CN104611275B (zh) * | 2015-02-11 | 2017-10-17 | 成都与康科技有限公司 | 植物乳杆菌ucn‑11菌株及其组合物和应用 |
-
2016
- 2016-08-23 CN CN201680049055.9A patent/CN108135948B/zh active Active
- 2016-08-23 ES ES16839703T patent/ES2909430T3/es active Active
- 2016-08-23 DK DK16839703.2T patent/DK3341001T3/da active
- 2016-08-23 PL PL16839703T patent/PL3341001T3/pl unknown
- 2016-08-23 US US15/753,692 patent/US10632159B2/en active Active
- 2016-08-23 WO PCT/SE2016/050787 patent/WO2017034460A1/en active Application Filing
- 2016-08-23 KR KR1020187005513A patent/KR102656709B1/ko active IP Right Grant
- 2016-08-23 AU AU2016312870A patent/AU2016312870B2/en active Active
- 2016-08-23 RU RU2018105964A patent/RU2738803C2/ru active
- 2016-08-23 EP EP16839703.2A patent/EP3341001B1/en active Active
- 2016-08-23 CA CA2995071A patent/CA2995071A1/en active Pending
- 2016-08-23 BR BR112018003123-2A patent/BR112018003123B1/pt active IP Right Grant
- 2016-08-23 MX MX2018002093A patent/MX2018002093A/es unknown
- 2016-08-23 JP JP2018510510A patent/JP6957452B2/ja active Active
-
2018
- 2018-02-16 IL IL257568A patent/IL257568A/en unknown
- 2018-02-23 ZA ZA2018/01266A patent/ZA201801266B/en unknown
-
2023
- 2023-03-31 AU AU2023201997A patent/AU2023201997A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DK3341001T3 (da) | 2022-03-21 |
| ZA201801266B (en) | 2019-06-26 |
| EP3341001A1 (en) | 2018-07-04 |
| US10632159B2 (en) | 2020-04-28 |
| PL3341001T3 (pl) | 2022-07-04 |
| RU2018105964A (ru) | 2019-09-26 |
| KR102656709B1 (ko) | 2024-04-09 |
| CN108135948B (zh) | 2022-04-12 |
| JP2018526370A (ja) | 2018-09-13 |
| JP6957452B2 (ja) | 2021-11-02 |
| MX2018002093A (es) | 2018-09-12 |
| RU2018105964A3 (pt) | 2020-01-28 |
| WO2017034460A1 (en) | 2017-03-02 |
| AU2023201997A1 (en) | 2023-05-04 |
| AU2016312870A1 (en) | 2018-03-08 |
| BR112018003123B1 (pt) | 2021-09-28 |
| IL257568A (en) | 2018-04-30 |
| EP3341001B1 (en) | 2021-12-29 |
| EP3341001A4 (en) | 2019-07-03 |
| AU2016312870B2 (en) | 2023-04-20 |
| RU2738803C2 (ru) | 2020-12-17 |
| KR20180041144A (ko) | 2018-04-23 |
| ES2909430T3 (es) | 2022-05-06 |
| US20180243353A1 (en) | 2018-08-30 |
| CN108135948A (zh) | 2018-06-08 |
| CA2995071A1 (en) | 2017-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018003123A2 (pt) | composição, enema, cepa isolada, método para tratamento e/ou prevenção de uma condição gastrointestinal, e, uso de uma composição, de um enema ou de uma ou mais de uma cepa bacteriana isolada | |
| MX2020002727A (es) | Nuevo uso para tratamiento de infecciones por clostridium difficile. | |
| BR112018077266A2 (pt) | composições compreendendo cepas bacterianas | |
| PH12019502725A1 (en) | Use of lactic acid bacteria to treat or prevent at least one of postnatal depression and postnatal anxiety | |
| CO2018010954A2 (es) | Nuevo uso médico de probioticos | |
| BR112015025256A8 (pt) | Cepas probióticas para uso no tratamento ou prevenção da osteoporose | |
| SA517390513B1 (ar) | تركيبات تشتمل على سلالات بكتيرية | |
| BR112017013233A2 (pt) | bacteriófago clo-pep-1 de clostridium perfringens inovador e uso do mesmo para a inibição de proliferação de clostridium perfringens | |
| AR106800A1 (es) | Composiciones que comprenden cepas bacterianas | |
| AR106768A1 (es) | Composiciones que comprenden cepas bacterianas | |
| SA113340703B1 (ar) | سلالة جديدة من بكتيريا Lactobacillus Crispatus | |
| BR112015026773A2 (pt) | cepas bacterianas que têm atividade antimicrobiana e composições de controle biológico que compreendem as mesmas | |
| BR112012033212A2 (pt) | uso de lactobacillo inibindo a produção de gás de bactéria coliforme isolada em infantes afetados por cólica | |
| CO2018006947A2 (es) | Novedoso bacteriófago pas-mup-1 de pasteurella multocida y su uso para inhibir la proliferación de pasteurella multocida | |
| BR112017013238A2 (pt) | bacteriófago esc-cop-1 de e. coli do tipo f18 produtora de toxina shiga inovador e uso do mesmo para a inibição de proliferação de e. coli do tipo f18 produtora de toxina shiga | |
| CO2019010062A2 (es) | Novedoso bacteriófago clo-pep-2 de clostridium perfringens y su uso para inhibir la proliferación de clostridium perfringens | |
| PH12015500091A1 (en) | Non-pathogenic f18 e.coli strain and use thereof | |
| BR112017023636A2 (pt) | suplemento dietético | |
| AR111885A1 (es) | Composiciones que comprenden cepas bacterianas | |
| WO2018004224A3 (ko) | 신규 스포리치아과 미생물 및 그의 용도 | |
| BR112018072511A2 (pt) | métodos para selecionar uma cepa bacteriana e para profilaxia, inibição e/ou tratamento de uma alergia, cepa, e, composição antialérgica | |
| CL2017001818A1 (es) | Bacteria de ácido láctico y su uso para el tratamiento de mastitis | |
| PH12019502239A1 (en) | Lactic acid bacteria, methods and uses thereof | |
| PE20141942A1 (es) | Composicion bionematicida y metodo para el control de nematodos fitopatogenos utilizando la misma | |
| CA2913067C (fr) | Utilisation d'une bacterie isolee du genre pseudoalteromonas, cyclolipopeptides et leurs utilisations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/08/2016, OBSERVADAS AS CONDICOES LEGAIS. |